Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high
(MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint
inhibitor (ICI) monotherapy is the treatment of choice. However, different molecular
mechanisms drive the development of dMMR/MSI-H tumors, including germline mutations in
canonical MMR genes (Lynch syndrome), somatically acquired MMR gene mutations (Lynch-like),
and homozygous methylation of the MLH1 gene promoter (sporadic). There is increasing evidence
that patients with sporadic MMRd EC have a worse response to ICI monotherapy than those with
Lynch/Lynch-like tumors. Antiangiogenic therapy can relieve immunosuppression through blood
vessel normalization and the oxygen metabolism pathway, thereby having a synergistic effect
with ICIs. Anlotinib is an oral anti-angiogenic tyrosine kinase inhibitor (TKI). Camrelizumab
is a fully humanized, high-affinity monoclonal antibody against PD-1. The purpose of this
trial is to assess the efficacy and safety and tolerability of anlotinib plus camrelizumab in
recurrent EC patients with sporadic MMRd tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University